Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in...